Profile data is unavailable for this security.
About the company
NexImmune, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing an approach to immunotherapy designed to employ the body’s own T cells to generate an immune response that mimics natural biology. Its product candidates include NEXI-001 in acute myeloid leukemia (AML); NEXI-002 in multiple myeloma (MM), and NEXI-003, a solid tumor product candidate for Human papillomavirus (HPV) related cancers. The Company provides Artificial Immune Modulation (AIM), which is a nanoparticle technology platform. Its AIM technology enables it to construct nanoparticles that function as synthetic dendritic cells capable of directing a specific T cell-mediated immune response. The AIM nanoparticles employ signaling proteins to deliver instructions to T cells directing a desired immune response. The Company is also developing new AIM nanoparticle constructs and modalities for clinical evaluation in oncology and autoimmune disorders.
- Revenue in USD (TTM)0.00
- Net income in USD-32.34m
- Incorporated2011
- Employees6.00
- LocationNeximmune Inc9119 Gaither RoadGAITHERSBURG 20878United StatesUSA
- Phone+1 (301) 825-9810
- Fax+1 (302) 636-5454
- Websitehttps://www.neximmune.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Alzamend Neuro Inc | 0.00 | -15.16m | 4.47m | 4.00 | -- | -- | -- | -- | -2.32 | -2.32 | 0.00 | -0.4146 | 0.00 | -- | -- | 0.00 | -265.85 | -- | -496.81 | -- | -- | -- | -- | -- | -- | -1,736.10 | -- | -- | -- | -- | -20.35 | -- | -- | -- |
| Exicure Inc | 23.79m | 3.07m | 4.49m | 7.00 | 0.406 | 0.4625 | 1.09 | 0.1887 | 1.28 | 1.28 | 3.86 | 1.12 | 0.8729 | -- | -- | 1,830,000.00 | 11.25 | -41.75 | 18.34 | -55.57 | -- | -- | 12.88 | -302.07 | -- | -- | 0.00 | -- | 6,068.12 | 24.29 | 95.97 | -- | -59.57 | -- |
| Alterola Biotech Inc | 0.00 | -2.88m | 4.51m | 1.00 | -- | -- | -- | -- | -0.0027 | -0.0027 | 0.00 | -0.001 | 0.00 | -- | -- | 0.00 | -47.24 | -- | -63.88 | -- | -- | -- | -- | -- | 0.0019 | -- | -- | -- | -- | -- | 73.07 | -- | -- | -- |
| GT Biopharma Inc | 0.00 | -9.64m | 4.51m | 2.00 | -- | 0.8501 | -- | -- | -7.04 | -7.04 | 0.00 | 3.85 | 0.00 | -- | -- | 0.00 | -64.24 | -205.36 | -90.39 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 63.62 | -- | -- | -- |
| NovaBay Pharmaceuticals Inc | 14.23m | -18.43m | 4.54m | 24.00 | -- | -- | -- | 0.319 | -3.11 | -3.11 | 1.44 | 0.005 | 1.41 | 2.91 | 11.08 | 593,041.70 | -108.92 | -61.51 | -185.74 | -83.89 | 54.47 | 59.99 | -77.22 | -86.47 | 0.7462 | -- | 0.8629 | -- | 2.24 | 3.32 | -2.66 | -- | -15.46 | -- |
| 4Cable TV International Inc | 758.68k | -3.14m | 4.66m | 0.00 | -- | -- | -- | 6.14 | -0.0624 | -0.0624 | 0.0157 | -0.0412 | 1.07 | 1.84 | 25.22 | -- | -441.73 | -82.30 | -- | -308.10 | 29.92 | -- | -414.41 | -47.62 | 0.0064 | -0.5271 | -- | -- | -0.0914 | -- | -731.54 | -- | -- | -- |
| CeCors Inc | -100.00bn | -100.00bn | 4.68m | 6.00 | -- | -- | -- | -- | -- | -- | -- | -0.0163 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 22.70 | -- | -- | -- |
| Neximmune Inc | 0.00 | -32.34m | 4.72m | 6.00 | -- | 1.05 | -- | -- | -30.86 | -30.86 | 0.00 | 3.29 | 0.00 | -- | -- | 0.00 | -125.24 | -115.07 | -178.52 | -165.07 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 48.25 | -- | -44.65 | -- |
| Cingulate Inc | 0.00 | -22.50m | 4.78m | 13.00 | -- | 1.23 | -- | -- | -22.66 | -22.66 | 0.00 | 0.6419 | 0.00 | -- | -- | 0.00 | -355.56 | -- | -1,198.96 | -- | -- | -- | -- | -- | -- | -33.88 | 0.0054 | -- | -- | -- | -33.14 | -- | -- | -- |
| Ensysce Biosciences Inc | 2.23m | -10.63m | 4.78m | 7.00 | -- | -- | -- | 2.14 | -5.28 | -5.28 | 0.9876 | -0.1026 | 0.5191 | -- | 11.92 | 318,645.70 | -247.32 | -17.68 | -- | -19.42 | -- | -- | -476.40 | -715.78 | -- | -30.28 | 4.20 | -- | -11.61 | -- | 57.64 | -- | -- | -- |
| Mystic Holdings Inc | -100.00bn | -100.00bn | 4.88m | 79.00 | -- | 0.1954 | -- | -- | -- | -- | -- | 0.2155 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.2228 | -- | 0.1849 | -- | 199.82 | -- | 34.32 | -- | -- | -- |
| Pacific Software Inc | 0.00 | -77.46k | 4.91m | 0.00 | -- | 0.3008 | -- | -- | -0.1832 | -0.1832 | 0.00 | 0.7646 | 0.00 | -- | -- | -- | -26.19 | -620.48 | -66.38 | -- | -- | -- | -- | -- | -- | -6.29 | 0.00 | -- | -- | -- | -13.29 | -- | -- | -- |
| China Pharma Holdings Inc | 7.01m | -3.08m | 4.93m | 231.00 | -- | 0.4738 | -- | 0.7025 | -1.06 | -1.06 | 2.07 | 0.7016 | 0.4094 | 2.18 | 15.14 | 30,351.95 | -17.98 | -29.66 | -41.91 | -55.25 | -4.01 | 6.47 | -43.91 | -73.09 | 0.332 | -8.42 | 0.3121 | -- | -13.48 | -10.68 | 22.50 | -- | -25.78 | -- |
| Gold River Productions Inc. | -100.00bn | -100.00bn | 4.95m | 1.00k | -- | 7.63 | -- | -- | -- | -- | -- | 0.0005 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -100.11 | -- | -- | -- |
| Halberd Corp | 281.24k | 25.34k | 4.96m | 3.00 | 3.36 | -- | 195.50 | 17.64 | 0.0023 | 0.0023 | 0.0018 | -0.0002 | 0.1449 | 0.0303 | 2.52 | -- | 1.31 | -- | 4.58 | -- | 50.00 | -- | 9.01 | -- | 0.2661 | 1.35 | 1.02 | -- | 271.52 | -- | -60.11 | -- | -- | -- |
Data as of May 17 2024. Currency figures normalised to Neximmune Inc's reporting currency: US Dollar USD
10.67%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Slate Path Capital LPas of 31 Dec 2023 | 37.00k | 3.13% |
| Adage Capital Management LPas of 31 Dec 2023 | 32.05k | 2.71% |
| EPIQ Capital Group LLCas of 31 Dec 2023 | 15.62k | 1.32% |
| PNC Bank, NA (Investment Management)as of 31 Mar 2024 | 12.64k | 1.07% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 12.01k | 1.02% |
| Raymond James & Associates, Inc. (Invt Mgmt)as of 31 Mar 2024 | 10.80k | 0.91% |
| Comerica Bank (Investment Management Texas)as of 31 Dec 2023 | 3.26k | 0.28% |
| Tower Research Capital LLCas of 31 Dec 2023 | 1.80k | 0.15% |
| RBC Dominion Securities, Inc.as of 31 Dec 2023 | 1.05k | 0.09% |
| BNP Paribas Financial Marketsas of 31 Mar 2024 | 41.00 | 0.00% |
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
